Abbott (NYSE:ABT) said today that it won national reimbursement in Japan for its everolimus-eluting stent, Xience Sierra, which is designed to treat patients with coronary artery disease.
The company’s latest drug-eluting device features a thinner profile, increased flexibility and longer lengths than previous stents, according to Abbott. The healthcare firm said it developed Xience Sierra to help cardiologists treat the complex lesions that make up nearly 70% of cases of coronary artery disease.
Get the full story at our sister site, Drug Delivery Business News.
The post Abbott’s Xience Sierra drug-eluting coronary stent wins reimbursement in Japan appeared first on MassDevice.
from MassDevice https://ift.tt/2jo4twr
Cap comentari:
Publica un comentari a l'entrada